REPLICEL LIFE SCIENCES INC.

(REPCF)
Delayed OTC Markets  -  05/26 09:30:01 am EDT
0.1000 USD   +5.49%
03/29REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets - Form 6-K
PU
03/22RepliCel Announces Non-brokered Private Placement
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/29/2021 EDT

RepliCel Life Sciences Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was CAD 0.836082 million compared to CAD 0.597994 million a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.02 a year ago. For the nine months, net loss was CAD 3.24 million compared to CAD 1.33 million a year ago. Basic loss per share from continuing operations was CAD 0.1 compared to CAD 0.05 a year ago.


© S&P Capital IQ 2021
All news about REPLICEL LIFE SCIENCES INC.
03/29REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted fo..
PU
03/22RepliCel Announces Non-brokered Private Placement
AQ
03/21RepliCel Life Sciences Inc. announced that it expects to receive CAD 1.5 million in fun..
CI
2021REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
2021REPLICEL LIFE SCIENCES : Closed Final Tranche of Strategic Investment Commitment
PU
2021RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido
CI
2021RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in fundi..
CI
2021RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.99892 million in..
CI
2021RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
More news
Financials
Sales 2020 0,35 M 0,28 M 0,28 M
Net income 2020 -1,58 M -1,24 M -1,24 M
Net Debt 2020 0,54 M 0,42 M 0,42 M
P/E ratio 2020 -2,90x
Yield 2020 -
Capitalization 5,97 M 4,67 M 4,67 M
EV / Sales 2019 25,8x
EV / Sales 2020 22,0x
Nbr of Employees 1
Free-Float 49,9%
Chart REPLICEL LIFE SCIENCES INC.
Duration : Period :
RepliCel Life Sciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Robert Lee Buckler President, CEO, Secretary & Director
Simon S. Ma Chief Financial Officer & Finance Director
David M. Hall Chairman
Rolf Hoffmann Chief Medical Officer
Kevin McElwee Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLICEL LIFE SCIENCES INC.-44.84%5
GILEAD SCIENCES, INC.-11.21%80 866
REGENERON PHARMACEUTICALS, INC.8.22%73 638
VERTEX PHARMACEUTICALS22.79%68 965
BIONTECH SE-38.65%38 433
WUXI APPTEC CO., LTD.-22.01%37 870